EE30 Economic Impact of Trilaciclib for Chemotherapy-Induced Myelosuppression (CIM) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Economic Evaluation from the Provider and Patient-Caregiver Perspectives in the United States
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.282
https://www.valueinhealthjournal.com/article/S1098-3015(22)00483-1/fulltext
Title :
EE30 Economic Impact of Trilaciclib for Chemotherapy-Induced Myelosuppression (CIM) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Economic Evaluation from the Provider and Patient-Caregiver Perspectives in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00483-1&doi=10.1016/j.jval.2022.04.282
First page :
Section Title :
Open access? :
No
Section Order :
10250